GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Equity-to-Asset

AP Biosciences (ROCO:6945) Equity-to-Asset : 0.95 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AP Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$1,786.65 Mil. AP Biosciences's Total Assets for the quarter that ended in Jun. 2024 was NT$1,889.71 Mil.

The historical rank and industry rank for AP Biosciences's Equity-to-Asset or its related term are showing as below:

ROCO:6945' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.88   Med: 0.95   Max: 1
Current: 0.95

During the past 4 years, the highest Equity to Asset Ratio of AP Biosciences was 1.00. The lowest was 0.88. And the median was 0.95.

ROCO:6945's Equity-to-Asset is ranked better than
94.6% of 1538 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6945: 0.95

AP Biosciences Equity-to-Asset Historical Data

The historical data trend for AP Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences Equity-to-Asset Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.99 0.96 1.00 0.88

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial - 1.00 0.90 0.88 0.95

Competitive Comparison of AP Biosciences's Equity-to-Asset

For the Biotechnology subindustry, AP Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AP Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AP Biosciences's Equity-to-Asset falls into.



AP Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AP Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=784.106/890.756
=0.88

AP Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=1786.648/1889.711
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AP Biosciences  (ROCO:6945) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


AP Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AP Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AP Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines